Anti-Human PCSK9 Recombinant Antibody (Bococizumab) (CAT#: TAB-H10)

Figure 1 Effect of Antidrug Antibodies on the Durability of Low-Density Lipoprotein (LDL) Cholesterol Lowering and on Plasma Bococizumab and PCSK9 Levels.

Panel A shows the effect of generalized antidrug antibodies (ADAs) on LDL cholesterol levels among the patients who received placebo and among those who received bococizumab, according to whether the patients were ADA-negative throughout the trial, had ADA titers in the lowest two thirds of maximum titers (<1:1176) during follow-up, had ADA titers in the highest third of titers (≥1:1176) during follow-up, or were in the subgroup with ADA titers in the top 10% (≥1:5674). The light blue bars indicate prevalent rates of antibodies at each time point, and the dark blue bars the cumulative incidence of antibody positivity during follow-up. Panel B shows plasma bococizumab levels and Panel C total plasma proprotein convertase subtilisin–kexin type 9 (PCSK9) levels over time, according to the ADA titer. Panel D shows the effect of the neutralizing antibody (NAb) titer on LDL cholesterol levels.

Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.

Figure 2 Variability in the Reduction in LDL Cholesterol Levels, According to the Presence or Absence of Antidrug Antibodies (ADAs).

Waterfall plots for individual patients who received bococizumab show the percent change from baseline in LDL cholesterol levels at 12 weeks (Panel A) and at 52 weeks among the patients in whom antidrug antibodies developed (Panel B) and among those in whom antidrug antibodies did not develop (Panel C). Data are limited to the patients who reported having received bococizumab in the 21 days before the measurement of LDL cholesterol.

Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.

Figure 1 Anti-Human PCSK9 Recombinant Antibody (TAB-H10) in SDS-PAGE

Lane 1: Non-reduced
Lane 2: Reduced

Figure 2 Anti-Human PCSK9 Recombinant Antibody (TAB-H10) in HPLC

The purity of TAB-H10 was greater than 95% as determined by SEC-HPLC.